Status and phase
Conditions
Treatments
About
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
At least 18 years of age.
Histologically or cytologically confirmed advanced solid tumors
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Karnofsky Performance Status of 70 or higher with no clinically significant deterioration over the previous 2 weeks.
Acceptable liver, renal, endocrine, and hematologic function.
Other protocol-defined inclusion criteria may apply.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
270 participants in 3 patient groups
Loading...
Central trial contact
Clinical Operations
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal